Pregnancy SmartShop formulas

Comparison · Pregnancy Smart

Birth control alternatives while breastfeeding

Assigned clinical reviewerSharyn Harrison· CNM, NPDraft · pending clinical reviewUpdated

How do the options compare?

Options are stacked on five dimensions relevant to pregnancy use: mainstream OB guidance, pregnancy-specific evidence, dosing predictability, onset, and side-effect and interaction profile.

OptionStudied pregnancy doseGuideline supportNotes
Progestin-only pill, also called the mini pillOne pill daily; timing and backup rules differ for norethindrone, norgestrel, and drospirenone formulations.May start immediately postpartum when pregnancy is reasonably excluded under 2024 U.S. guidance.No estrogen. Evidence is generally reassuring for breastfeeding, but daily adherence matters and the acceptable late-pill window depends on the formulation.
Etonogestrel implantA clinician places one long-acting rod under the skin of the upper arm.May be placed immediately postpartum under 2024 U.S. guidance.Fewer than one typical user in 100 becomes pregnant in the first year. Irregular bleeding is common; available lactation evidence is reassuring.
Hormonal IUDA clinician places a levonorgestrel-releasing device in the uterus.May be placed immediately postpartum or later when pregnancy is reasonably excluded; it is not placed with postpartum uterine infection.Immediate placement is convenient but has a higher expulsion rate. Breastfeeding is linked to a relative rise in perforation risk, while the absolute risk remains low.
Copper IUDA clinician places a hormone-free copper device in the uterus.May be placed immediately postpartum or later when pregnancy is reasonably excluded; it is not placed with postpartum uterine infection.No hormone and no expected milk-supply effect. Menstrual bleeding may become heavier, and postpartum placement carries more expulsion risk than interval placement.
DMPA contraceptive injection150 mg intramuscularly or 104 mg subcutaneously, repeated on the recommended injection schedule.May be given immediately postpartum under 2024 U.S. guidance after medical eligibility review.No estrogen. Return to ovulation can be delayed after the last injection, and the method cannot be removed once a dose is given.
Condoms and other barrier methodsUsed with each act of intercourse; no systemic medicine dose.Can be used during breastfeeding without a hormone-related milk-supply effect.External and internal condoms can also reduce sexually transmitted infection risk. Typical-use pregnancy rates are higher than with an IUD or implant.
Combined pill, patch, or ringContains estrogen plus a progestin; schedule varies by product.Not used before 21 days postpartum during breastfeeding; generally avoided through day 29. Days 30 to 42 depend on clot risk, followed by individual eligibility review.Early milk-supply evidence is inconsistent and based largely on older pill formulations. This option needs more timing discussion than progestin-only or nonhormonal choices.
  • The 2024 U.S. Selected Practice Recommendations allow progestin-only pills, the implant, and the contraceptive injection to start immediately postpartum when pregnancy is reasonably excluded, with method-specific backup guidance. 1
  • The 2024 U.S. Medical Eligibility Criteria classifies combined hormonal contraception as unacceptable before 21 days postpartum during breastfeeding and generally unsuitable from days 21 through 29. At 30 to 42 days, eligibility depends on additional clot-risk factors; after 42 days it is generally acceptable if no other contraindication applies. 2
  • A systematic review of 47 studies generally found no adverse breastfeeding, infant growth, or infant development signal with progestin-only pills, implants, injections, or hormonal IUDs, although study quality was poor to fair. 3
  • An updated IUD review found no adverse breastfeeding or infant outcome signal from copper IUD use and no broad increase in IUD adverse events during breastfeeding, but perforation risk was relatively higher while remaining uncommon in absolute terms. 4
  • A systematic review of combined oral contraceptives found inconsistent breastfeeding effects, especially with early initiation, and emphasized that the evidence largely came from older formulations and poor-to-fair-quality studies. 5

Which option makes sense?

Options in this comparison can differ substantially in suitability. Please consult your healthcare provider to interpret the evidence, limitations, and cautions before choosing an option or changing your plan.

Disclosure: Pregnancy Smart is a supplement maker. The options compared above sit outside our own product line; this page describes their pregnancy evidence on its own merits.

Frequently asked questions

What birth control is most compatible with breastfeeding?

Progestin-only pills, the implant, hormonal or copper IUDs, the contraceptive injection, and barrier methods are all options during breastfeeding. The best fit depends on desired effectiveness, bleeding preferences, daily adherence, postpartum timing, clot risk, and plans for another pregnancy.

Does birth control reduce milk supply?

Progestin-only and nonhormonal birth control generally has reassuring breastfeeding evidence. Estrogen-containing pills have inconsistent milk-supply findings, particularly when started early, and current U.S. guidance also limits their use soon after birth because postpartum clot risk is elevated.

What is the mini pill?

The mini pill is a progestin-only oral contraceptive without estrogen. Norethindrone, norgestrel, and drospirenone versions have different late-pill and backup rules, so the exact product name matters even though all are commonly grouped as progestin-only pills.

Can the regular combined birth control pill be used while breastfeeding?

Combined pills contain estrogen and a progestin. During breastfeeding, U.S. guidance rules them out before 21 days postpartum and generally advises against them from days 21 through 29. At 30 to 42 days, clot-risk factors determine eligibility. After 42 days, they are generally acceptable when no other contraindication applies.

Does an IUD affect breast milk?

Copper IUD evidence shows no adverse breastfeeding or infant-growth signal. Evidence for levonorgestrel IUDs is also generally reassuring. Immediate postpartum placement offers convenience but has a higher expulsion rate than later placement, and breastfeeding raises relative perforation risk while absolute risk stays low.

When can birth control start after delivery?

Several options can start immediately postpartum, including progestin-only pills, the implant, DMPA injection, and an IUD in eligible patients. Estrogen-containing pills, patches, and rings follow a later timeline because postpartum clot risk is highest early after birth.

Is the implant likely to change breastfeeding success?

The contraceptive implant's breastfeeding evidence is reassuring overall. Systematic reviews and randomized timing studies generally have not found meaningful differences in lactation or infant growth between immediate and later placement, though individual milk-supply concerns still deserve evaluation.

Can breastfeeding alone work as birth control?

Lactational amenorrhea works only when three conditions remain true: the baby is younger than 6 months, menstrual bleeding has not returned, and feeding is fully or nearly fully at the breast. If any condition changes, use another contraceptive method.

Which breastfeeding birth control needs the least daily attention?

An IUD or implant requires the least daily attention and has a first-year typical-use pregnancy rate below one in 100. A progestin-only pill requires regular daily dosing, while condoms require correct use with each act of intercourse.

Related in the library

References

  1. U.S. Selected Practice Recommendations for Contraceptive Use, 2024

    CDC via PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC11340200/

  2. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024

    CDC via PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC11315372/

  3. Progestogen-only contraceptive use among breastfeeding women: a systematic review

    PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC11376434/

  4. The safety of intrauterine devices during breastfeeding: an updated systematic review

    PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC12703274/

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.